News | April 26, 2024
Divi's Laboratories to expand capacity at an outlay of approx. Rs. 700 Cr
The proposed facility is expected to be operational around January, 2027
The proposed facility is expected to be operational around January, 2027
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Open a printable version of this pageEmail the URL of this page to a friend
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Subscribe To Our Newsletter & Stay Updated
